

Seirbhís Aisíoca Príomhchúraim
Bealach amach 5 an M50, Án Bóthar Thuaidh, Fionnghlas,
Baile Átha Cliath 11. D11 XKF3



Primary Care Reimbursement Service
Exit 5, M50, North Road, Finglas, Dublin 11,
D11 XKF3

Mr. Marc McSharry, T.D.
Dáil Éireann,
Leinster House,
Kildare Street,
Dublin 2.

24 July, 2019

PQ: 30372/19

To ask the Minister for Health the oncology medicines that had a health technology assessment completed by the NCPE since 2016 and are not reimbursed by the HSE in tabular form; and if he will make a statement on the matter. -Marc MacSharry

Dear Deputy McSharry,

The Health Service Executive has been requested to reply directly to you in the context of the above Parliamentary Question (Reference 30372/19), which you submitted to the Minister for Health for response.

The HSE has not reached a final decision to refuse to reimburse any cancer medicine in time period between 2016 and 2019. A number of medicine applications and commercial negotiations have been ongoing in relation to cancer medicines, which have completed assessments with a view to arriving at acceptable pricing positions that would enable reimbursement.

Please see the attached table listing an update on the relevant medicines:

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Kieran Healy', written over a horizontal line.

Kieran Healy
Primary Care Eligibility & Reimbursement Service

Encl.

Generic Name	Brand	Indication	Company	Position as at June 2019
Pertuzumab	Perjeta	Neo-adjuvant treatment of breast cancer	Roche	On Drugs Group Agenda
Ruxolitinib	Jakavi	Polycythaemia Vera	Novartis	Discussions ongoing seeking commercial solution
Osimertinib	Tagrisso	2nd Line Non-small cell lung cancer	AstraZeneca	Drugs Group recommendation under consideration at HSE Senior Leadership Team
Nivolumab	Opdivo	Bladder Cancer 2L	BMS	Discussions ongoing
Avelumab	Bavencio	1st line Metastatic Merkel Cell Carcinoma	Merck Serono	Additional clinical information being reviewed
Pertuzumab	Perjeta	Adjuvant Breast Cancer	Roche	On Drugs Group Agenda
Daratumumab in combination with Bortezomib and Dexamethasone	Darzalex	Multiple Myeloma (Combination Therapy)	Janssen	Drugs Group recommendation under consideration at HSE Senior Leadership Team
Pembrolizumab	Keytruda	2nd Line Urothelial Cancer	MSD	Discussions ongoing